These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37406784)

  • 1. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor.
    Koschinsky ML; Stroes ESG; Kronenberg F
    Pharmacol Res; 2023 Aug; 194():106843. PubMed ID: 37406784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a).
    Kronenberg F
    Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees.
    Kronenberg F; Mora S; Stroes ESG
    Curr Opin Lipidol; 2022 Dec; 33(6):342-352. PubMed ID: 36251423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.
    Di Fusco SA; Arca M; Scicchitano P; Alonzo A; Perone F; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F
    Heart; 2022 Dec; 109(1):18-25. PubMed ID: 35288443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein (a): When to Measure and How to Treat?
    Rhainds D; Brodeur MR; Tardif JC
    Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a): cardiovascular risk and emerging therapies.
    Fujino M; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
    Boffa MB; Koschinsky ML
    Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Lp(a): Guidance for Identifying and Managing Patients.
    Hilleman DE; Vacek JL; Backes JM
    South Med J; 2024 Apr; 117(4):208-213. PubMed ID: 38569611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
    Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
    Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky ML; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Atherosclerosis; 2023 Jun; 374():107-120. PubMed ID: 37188555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
    Nordestgaard BG; Langsted A
    J Lipid Res; 2016 Nov; 57(11):1953-1975. PubMed ID: 27677946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
    Swerdlow DI; Rider DA; Yavari A; Wikström Lindholm M; Campion GV; Nissen SE
    Cardiovasc Res; 2022 Mar; 118(5):1218-1231. PubMed ID: 33769464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Vuorio A; Watts GF; Kovanen PT
    Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).
    Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL
    Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.